Lantheus Medical Imaging to Present New Data on Novel PET Cardiac and Heart Failure Imaging Agents at the American College of Cardiology 59th Annual Scientific Session in Atlanta
N. BILLERICA, Mass. (March 9, 2010) – Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that new data for BMS747158, the company’s novel drug candidate in clinical development as a Positron Emission Tomography (PET) perfusion imaging agent, will be featured in an oral presentation at the American College of Cardiology 59th Annual Scientific Session taking place March 14-16, 2010 in Atlanta. BMS747158 is now known by the generic name flurpiridaz F 18. In addition, new data on LMI1195, the company’s innovative PET imaging agent in clinical studies for heart failure, will be highlighted in a poster presentation.
The oral presentation will feature new data from a single center comparing flurpiridaz F 18, currently in Phase 2 clinical trials, with rest-stress SPECT imaging for the detection and evaluation of coronary artery disease (CAD). Jamshid Maddahi, M.D., F.A.C.C., Professor of Molecular and Medical Pharmacology (Nuclear Medicine) and Medicine (Cardiology) at the David Geffen School of Medicine at UCLA and the Lead Principal Investigator of the study, will present these findings from his center. Preclinical data for LMI1195, a novel F-18 small molecule tracer for heart failure imaging currently in Phase 1 clinical trials, will be presented by Ming Yu, M.D., Ph.D., Sr. Research Investigator, Lantheus Medical Imaging, Inc.
“We are pleased that the American College of Cardiology has chosen to feature two of our pipeline products at its upcoming annual meeting. These agents have the potential to improve the evaluation of coronary artery disease and heart failure, both areas of significant unmet medical need. We believe that PET technology, combined with our F-18 labeled tracers, could provide significant advancements in diagnostic imaging for better disease detection and management in patients with cardiovascular disease,” said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging, Inc. “Lantheus Medical Imaging is committed to developing a new generation of diagnostic products that cardiologists can use to advance patient care.”
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medicine for more than 50 years, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The company’s proven success in discovering, developing and marketing innovative medical imaging agents provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVARTM (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has more than 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.